A Phase 1b-2, Multicenter, Trial To Evaluate The Efficacy, Safety, Pharmacokintetics, And Pharmacodynamics Of REC-4881 in Patients With Familial Adenomatous Polyposis (FAP)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 May 2024 According to a Recursion Pharmaceuticals media release, enrollment in Part 2 has commenced and company expects to share Phase 2 safety and preliminary efficacy data in H1 2025.
27 Feb 2024 According to a Recursion Pharmaceuticals media release, the part 1 is complete with FPI for Part 2 anticipated in H1 2024.
19 Jan 2024 The protocol has been amended to change study phase Phase 1/Phase 2 from phase 1, and now patients with an age of 55 years can also participate in the study with respect to the addition of subjects, the increase in arms, and the change in time frame.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com